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Mendelian diseases which predispose to ovarian tumours include
familial breast/ovarian cancer (resulting from germline BRCA1
and BRCA2 mutations), Gorlin syndrome (resulting from PTCH
mutations), hereditary non-polyposis colon cancer (HNPCC,
resulting from mismatch repair gene mutations) and Peutz-Jeghers
syndrome (PJS, MIM175200). PJS is characterized by hamar-
tomatous polyps of the gastrointestinal tract and other epithelia,
and by freckling of the lips, buccal mucosa and other sites
(Tomlinson and Houlston, 1997). PJS patients have an increased
risk of neoplasia of multiple sites. This risk may approach a 20-
fold increase over the general population if all organs are consid-
ered, although the increased risk for any particular site is
necessarily more modest (Murday and Slack, 1989).
The gene for PJS has recently been shown to be a serine/
threonine kinase, known as LKB1 or STK11 (Genbank U63333),
which maps to chromosome sub-band 19p13.3 (Hemminki et al,
1997, 1998). This gene acts as a tumour suppressor in the
hamartomatous polyps of PJS patients and probably also acts as
a tumour suppressor in the other neoplasms that develop in PJS
patients (Wang et al, 1999). It is not clear whether these neoplasms
develop from hamartomas, or whether the LKB1 locus plays a role
in a different genetic pathway of tumour growth, although the
former is more likely.
Peutz-Jeghers patients are at increased risk of a number of gynae-
cological neoplasms. These include benign and malignant ovarian
lesions, especially granulosa cell tumours (GCTs), in addition to
adenoma malignum of the cervix and endometrial adenocarcinoma.
Ovarian adenocarinomas show a relatively high frequency of loss of
heterozygosity (allele loss, LOH) on chromosome 19p13.3 (Sato et
al, 1991; Osborne and Leech, 1994; Amfo et al, 1995; Pejovic,
1995). LKB1 is therefore a good candidate for involvement in the
pathogenesis of sporadic tumours of the ovary. We have analysed a
set of sporadic adenocarcinomas of the ovary for allele loss on chro-
mosome 19p13.3 and then screened these tumours and a set of
ovarian granulosa cell tumours for mutations in the LKB1 gene.
METHODS
Using standard methods, DNA was extracted from 60 samples of
unselected, fresh-frozen sporadic adenocarcinomas of the ovary
and matched normal tissue or blood. After microdissection to
enrich for tumour material, DNA was extracted from fixed,
paraffin-embedded samples of 12 GCTs of the ovary using
proteinase K digestion and the Qiagen tissue extraction kit. None
of these cases had known clinical or familial features suggestive of
PJS. Standard clinicopathological data (patient age, and tumour
grade and stage) were available from hospital records.
For allele loss analysis at LKB1, the D19S886 microsatellite
marker was used; this maps within 500 kb of LKB1 (http://www-
bio.llnl.gov/). About 50 ng of DNA from paired tumour/normal
samples from the ovarian adenocarcinoma patients were amplified
using the polymerase chain reaction (PCR) under standard condi-
tions. The forward primer had previously been end-labelled with
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g-32ATP using 3U of T4 polynucleotide kinase. Radio-labelled
products were electrophoresed through 6% denaturing polyacryl-
amide gels, dried and exposed to X-ray film for 24 h. Quantitation
of PCR products from tumours and the corresponding constitu-
tional DNA was achieved using the Molecular Dynamics
phoshorimager and software. Allele loss was scored if the area
under an allelic peak was reduced to < 50% of its original value
(relative to the other allele), thus making allowance for the pres-
ence of contaminating stromal tissue or inflammatory infiltrate in
some of the tumours.
Single-strand conformational polymorphism (SSCP) analysis
was performed on the tumour samples as the method of mutation
screening at LKB1. For the adenocarcinomas, published oligo-
nucleotides and reaction conditions were used for exon-by-exon
amplification of LKB1 in the PCR (Wang et al, 1998). For the
GCTs, new oligonucleotides were designed to produce shorter
PCR target sequences which were more likely to amplify success-
fully from fixed archival material in the PCR (Table 1). A PCR
protocol of 94°C (3 min) ´ 1, 94°C (1 min)/Ta °C (1 min)/72°C
(1 min)  ´ 35, 72°C (5 min) ´ 1 was used for the GCTs, with
the addition of 0.02% dimethyl sulphoxide (DMSO) and 0.1%
bovine serum albumin (BSA) to the reaction where necessary.
PCR products were heated to 90°C for 5 min and subjected to
electrophoresis on an 8% acrylamide gel (37.5:1 acrylamide:
bisacrylamide, 10% glycerol) under non-denaturing conditions at
20 mA for about 16 h. DNA was detected by silver-staining of gels
using standard methods. For all tumours with possible mutations
according to SSCP analysis, the appropriate exon was reamplified
from genomic DNA in the PCR, and purified PCR products were
sequenced in forward and reverse orientation using the ABI Ready
Reaction Dye Terminator Cycle Sequencing kit and the 373
sequencer. All sequencing reactions were performed in duplicate
and alongside samples with wild-type genotypes, and patient
samples with known germline mutations in LKB1.
RESULTS AND DISCUSSION
Allele loss was found at D19S886 in 12 of 49 (24%) informative
ovarian adenocarcinomas (out of the total of 60 studied). This is
apparently a somewhat lower frequency of allele loss on 19p than
found in some studies, but inspection of the data from these other
studies shows that our results are in agreement if the previous
analysis of multiple markers on 19p, the sample sizes used and the
different tumour types studied are taken into account. Sato et al
(1991) found allele loss at D19S20 (4 cM from D19S886) in five
of 19 (26%) adenocarcinomas of the ovary (map data from
Table 1 Oligonucleotides used for study of paraffin-embedded archival tumour material
Exon Oligo (F,R) Sequence Ta Product length
1 GB1727 AGG GCT GGC GGC GGG ACT CC 58 211
GB1936 TCC TTC ACC TTG CCG TAA GAG C
GB1920 GAC CTG CTG GGG GAA GGC TCT T 58 170
GB2090 AAC CAT CAG CAC CGT GAC TGG
2 GC1289 CTG ATA CAC CCC TGT CCT CTC TGT C 54 120
GC1409 AGG CCC CGC GGT CCC AAC AC
3 GD5531 CTC CAG AGC CCC TTT TCT G 59 255
GD5786 TCA ATG ACT ATC AGG CCA CG
4/5 GA826 GGC CCC AGG ACG GGT GTG TG 58 160
GA986 CCC TAG CAC GTG CCT ACC TC
GA951 GTG GCA CCC TCA AAA TCT CC 57 183
GA1134 TCC AGG CCG TTG GCA ATC TC
GA1071 ACC CGT TCG CGG CGG ACG 58 152
GA1223 AGT GTG CGT GTG GTG AGT GC
6 GA1659 TGA CTG ACC ACG CCT TTC TT 57 218
GA1877 CCC CCA ACC CTA CAT TTC TG
7 GA2412 CTC CTC GCC GGC TTC TCC TC 62 155
GA2567 CCC CAC CAC GCC CTG CTC TA
8 GA3439 GAC AGG CGC CAC TGC TTC TG 60 251
GA3690 GGA CAT CCT GGC CGA GTC AG
9 GE001 GTA AGT GCG TCC CCG TGG TG 59 337
GE338 GTG GCA TCC AGG CGT TGT CC
Figure 1 M1T mutation in granulosa cell humour. Wild type sequence is not
shown
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ftp://cedar.genetics.soton.ac.uk/pub/chrom19/map). Osborne and
Leech (1994) found allele loss at D19S177 (20 cM proximal to
D19S886) in four of ten (40%) ovarian adenocarcinomas of the
ovary. Amfo et al (1995) detected allele loss (in addition to one
putative rearrangement) in two of nine (22%) adenocarcinomas at
the INSR locus (23 cM proximal to D19S886). Our results do not
differ significantly from any of these other studies (c2 test, details
not shown). LKB1 therefore remained an excellent candidate gene
for acting as a tumour suppressor in ovarian tumorigenesis.
In a set of ten adenocarcinomas with LOH, in 35 other adenocarci-
nomas selected at random, and in 12 GCTs, a small number of variant
bands suggestive of somatic mutations at LKB1 was detected on
SSCP analysis. In all the carcinomas, these putative bandshifts were
shown on sequencing to be intronic polymorphisms or other intronic
variants with no predicted effect on mRNA or protein. A commonly
observed biallelic polymorphism (C/G, heterozygosity 44% in a
sample of 34 individuals) was found in intron 7 at the +8 splice donor
site. This polymorphism is found at approximately equal allele
frequencies (details not shown) in normal individuals, in PJS patients
and in tumours, and it almost certainly has no effect on mRNA
splicing; it may, however, be useful for future allele loss studies at the
LKB1 locus. No LKB1 mutations were found in the adenocarci-
nomas. Two mutations were, however, detected in one of the granu-
losa cell tumours (Figure 1): a mis-sense mutation affecting the
putative ‘start’ codon (ATG ® ACG, M1T); and a silent change in
exon 7 (CTT ®CTA, leucine). These variants were not present in the
germline. Analysis of the sequence showed that this tumour did not
exhibit allele loss at LKB1. No particular clinicopathological features
distinguished this granulosa cell tumour from any of the others.
It is not clear whether or not the M1T mutation in one of the gran-
ulosa cell tumours has any pathogenic effect. Certainly, it occurs
outside the kinase core (codons 50–337) in which most germline
mutations have been found (Hemminki et al, 1998). Although codon
1 provides the best candidate ‘start’ codon for LKB1 translation, there
are several alternative ‘start’ codons just downstream (at codons 11,
18 and 22) which may allow near-normal function of the LKB1
protein. Codon 22, in particular, is flanked by sequences which
suggest that it could function efficiently as an alternative initiator of
translation. It is even possible that the methionine at codon 1 is not
the usual ‘start’ site for LKB1. The M1T mutation has not, however,
been observed as a variant in over 50 other PJS patients, tumours and
normal individuals sequenced for exon 1 of LKB1.
SSCP only detects about 80% of mutations (Sheffield et al, 1993;
Ravnik et al, 1994; Vidal and Moller, 1994), and this figure may be
somewhat lower for some types of point mutation. We have not
excluded further possibilities for the involvement of LKB1 in
ovarian tumorigenesis, such as gene silencing by promoter methy-
lation, or hemi- or homozygous deletion of either locus (whether
the entire gene or whole exons). Thus, it remains possible that
mutations or transcriptional inactivation at LKB1 occur in a larger
proportion of ovarian tumours than we have reported. It remains
most likely, however, that – similar to that with the BRCA1 and
BRCA2 genes in familial breast/ovarian cancer – inherited variation
in LKB1 predisposes to ovarian tumours in PJS, but somatic muta-
tions in the same gene are rarely important for the pathogenesis of
sporadic tumours of this site. Occasional LKB1 mutations with
pathogenic effects have been found in cancers of the colon, testis,
lung and skin (Dong et al, 1998; Wanger et al, 1998; Rowan et al,
1999; Wang et al, 1999; Ylikorkala et al, 1999).
Although somatic LKB1 mutations may be important in the
pathogenesis of a minority of sporadic granulosa cell tumours, it is
most likely that LKB1 is not mutated in ovarian adenocarcinomas
and that the allele loss observed on chromosome 19p13.3 in these
cancers targets a different locus from LKB1. Whether or not INSR
is actually the gene involved, the combined data from previous
work and our study suggest that allele loss on 19p13.3 in ovarian
cancer targets a different locus from LKB1. Candidate genes in this
region of chromosome 19p include basigin, CDC34, PTPRS,
AMH, ICAM1, ICAM3 and CDKN2D.
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